On Biostatistics and Clinical Trials: Haybittle–Peto Boundary for Stopping the Trial for Efficacy or Futility at Interim Analysis
![A: Forest plot of Peto ORs of main glycemic end points (Glyc. Endp.),... | Download Scientific Diagram A: Forest plot of Peto ORs of main glycemic end points (Glyc. Endp.),... | Download Scientific Diagram](https://www.researchgate.net/publication/303484946/figure/fig3/AS:365368574005249@1464122064147/A-Forest-plot-of-Peto-ORs-of-main-glycemic-end-points-Glyc-Endp-as-defined-in-each.png)
A: Forest plot of Peto ORs of main glycemic end points (Glyc. Endp.),... | Download Scientific Diagram
![Interpretation of large-scale randomised evidence Need for reliable assessment of MODERATE effects on mortality Richard Peto Clinical Trial Service Unit. - ppt download Interpretation of large-scale randomised evidence Need for reliable assessment of MODERATE effects on mortality Richard Peto Clinical Trial Service Unit. - ppt download](https://slideplayer.com/4630980/15/images/slide_1.jpg)
Interpretation of large-scale randomised evidence Need for reliable assessment of MODERATE effects on mortality Richard Peto Clinical Trial Service Unit. - ppt download
Reflections on the design and analysis of clinical trials and meta-analyses in the 1970s and 1980s - Richard Peto, 2019
CLINICAL TRIAL METHODOLOGY The essential attributes of a good clinical trial are that it should address itself to an important i
![Protección integral para trial Mots Skin Pro | PLANETTRIAL | Tienda especializada en motos y bicicletas de trial Protección integral para trial Mots Skin Pro | PLANETTRIAL | Tienda especializada en motos y bicicletas de trial](https://media.v2.siweb.es/uploaded_thumb_medium/8094d12eb90345335d6994d7c932d86d/peto_integral_mots_skin_pro_tml.jpg)
Protección integral para trial Mots Skin Pro | PLANETTRIAL | Tienda especializada en motos y bicicletas de trial
CLINICAL TRIAL METHODOLOGY The essential attributes of a good clinical trial are that it should address itself to an important i
![Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study - The Lancet Oncology Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2001025258/2003893161/gr1.gif)